Insmed: Strong Sales of Brinsupri Lead to Significant Gains!
Reading Time: 2 minutes
Massive volume breakout: Insmed shares soar after phenomenal Q2 numbers and raised guidance. Drastic sales boom: Revenue from the lung medication Brinsupri surged by +48.7% in comparison to the previous quarter, reaching $309.2 million. Annual target raised: Management has increased revenue expectations for 2026 to up to $1.870 billion, surpassing Wall Street estimates. The American biopharmaceutical company Insmed has established itself as a highly specialized player in the field of severe and rare respiratory diseases in pulmonology....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
